keyword
https://read.qxmd.com/read/38451181/genetically-determined-telomere-length-as-a-risk-factor-for-hematological-malignancies-evidence-from-mendelian-randomization-analysis
#21
JOURNAL ARTICLE
Tian Fang, Zhihao Zhang, Kexing Ren, Liqun Zou
BACKGROUND: Over the past years, the exact correlation between telomere length and hematological malignancies was still not fully understood. METHODS: We performed a two-sample Mendelian randomization study to investigate the causal relationship between telomere length and hematological malignancies. We selected genetic instruments associated with telomere length. The genetic associations for lymphoid and hematopoietic malignant neoplasms were obtained from the most recent publicly accessible FinnGen study R9 data...
March 6, 2024: Aging
https://read.qxmd.com/read/38444525/long-term-follow-up-of-efficacy-and-safety-in-elderly-patients-with-chronic-myeloid-leukemia-treated-with-intermittent-low-dose-dasatinib-therapy
#22
Masahiro Imamura, Yusuke Nakamura, Daisuke Hidaka, Reiki Ogasawara, Kohei Okada, Junichi Sugita, Shuichi Ota
Intermittent low dose dasatinib therapy brought about a beneficial effect in elderly patients with chronic-phase chronic myeloid leukemia (CML-CP) without inducing severe adverse events (AEs). An 85-year-old male patient, who received twice-weekly, thrice-weekly, or four-times-weekly administration of 20 mg/day dasatinib after once-weekly administration, achieved a major molecular response two years after the start of dasatinib treatment and later sometimes achieved a deep molecular response, maintaining the efficacy for 11 years...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38444524/-igll5-controlled-by-super-enhancer-affects-cell-survival-and-myc-expression-in-mature-b-cell-lymphoma
#23
JOURNAL ARTICLE
Hiroki Hosoi, Shotaro Tabata, Hideki Kosako, Yoshikazu Hori, Tadashi Okamura, Yusuke Yamashita, Kota Fujimoto, Daiki Kajioka, Kentaro Suzuki, Motomi Osato, Gen Yamada, Takashi Sonoki
IGLL5 is shown to be located near super-enhancer (SE) in B-cell tumors, and this gene is frequently mutated and a target of translocation in B-cell tumors. These results suggest roles of the IGLL5 in tumorigenesis; however, its functional properties have been unclear. We found that two mature B-cell lymphoma cell lines expressed IGLL5 mRNA with Cλ1 segment. JQ1 treatment resulted in down-expression of IGLL5 , indicating that IGLL5 is controlled by SE. IGLL5 knockdown induced cell death with down-expression of MYC ...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38437804/a-scoping-review-of-otologic-manifestations-of-hematologic-malignancies
#24
JOURNAL ARTICLE
Mallory J Raymond, Allie Ottinger, M Andrew Rowley, Michael Bobian, Jim Dornhoffer, Emily Brennan, Habib G Rizk
OBJECTIVE: To examine the otologic and neurotologic symptoms, physical examination findings, and imaging features secondary to hematologic malignancies. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases, including PubMed, Scopus, and CINAHL, were searched for articles including patients with otologic manifestations of leukemia, lymphoma and multiple myeloma. Data collected included patient and study demographics, specific hematologic malignancy, timing and classification of otologic symptoms, physical examination findings, imaging features and methods of diagnosis...
February 29, 2024: Otology & Neurotology
https://read.qxmd.com/read/38436954/socioeconomic-status-and-overall-survival-among-patients-with-hematological-malignant-neoplasms
#25
JOURNAL ARTICLE
Lars Hernández Nielsen, Daniel Tuyet Kristensen, Lasse Hjort Jakobsen, Martin Bøgsted, Henrik Gregersen, Jakob Madsen, Marianne Tang Severinsen, Rasmus Froberg Brøndum
IMPORTANCE: In recent years, there has been a focus on reducing the socioeconomic gap in survival for hematological malignant neoplasms. Understanding recent developments is important to develop further intervention to improve care. OBJECTIVE: To investigate the temporal trend in associations of socioeconomic status (SES) with survival among 3 aggressive hematological malignant neoplasms: multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL)...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38433987/pomalidomide-improves-the-effectiveness-of-car-t-treatment-in-the-relapsed-and-refractory-multiple-myeloma-or-b-cell-leukemia-lymphoma-with-extramedullary-disease
#26
JOURNAL ARTICLE
Jie Zhao, Hui Yang, Junnan Ge, Linyu Li, Qiong Yao, Shaolong He, Qiujuan Zhu, Ruiui Ren, Chunrui Li, Liangming Ma, Weiwei Tian, Jia Wei
Relapsed and refractory multiple myeloma (RRMM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) have poor prognosis and high mortality, lack of effective therapeutic approaches. We reported for the first time that 6 patients with malignant hematological diseases with EMD received chimeric antigen receptor (CAR)-T treatment combined with pomalidomide, and CAR-T cells were treated with pomalidomide in vitro to determine its killing activity and cytokine secretion. Three patients with RRMM were given B cell maturation antigen (BCMA)-CAR-T therapy...
April 2024: Blood Sci
https://read.qxmd.com/read/38433500/sensitivity-specificity-and-accuracy-of-molecular-profiling-on-circulating-cell-free-dna-in-refractory-or-relapsed-multiple-myeloma-patients-results-of-mm-ep1-study
#27
JOURNAL ARTICLE
C Quivoron, J-M Michot, A Danu, H Lecourt, V Saada, K Saleh, V Vergé, S Cotteret, O A Bernard, V Ribrag
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular response and treatment resistance of patients with refractory/relapsed multiple myeloma (R/R MM). We evaluated the sensitivity and specificity of cfDNA compared to BMA CD138 positive myeloma plasma cells (PCs) in a series of 45 R/R MM patients using the 29-gene targeted panel (AmpliSeq) NGS. KRAS , NRAS , FAM46C , DIS3 , and TP53 were the most frequently mutated genes...
March 3, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38433043/real-world-survival-healthcare-resource-utilization-and-costs-among-u-s-elderly-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-r-gemox-in-the-relapsed-refractory-setting
#28
JOURNAL ARTICLE
Mahek Garg, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa A Doshi, Scott F Huntington
BACKGROUND: Little recent real-world evidence exists on overall survival, healthcare resource utilization (HCRU), and costs among R/R DLBCL patients treated with the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx), a widely-used regimen for patients ineligible for stem cell transplant due to age or comorbidities. PATIENTS AND METHODS: This retrospective analysis used 2014 to 2019 U.S. Medicare claims. Individuals aged ≥66 years with a new DLBCL diagnosis between October 1, 2015 and December 31, 2018 and continuous fee-for-service Medicare Part A, B, and D coverage in the 12 months pre- and postindex were followed to identify the sample of patients with evidence of R-GemOx treatment in the second-line (2L) or third-line (3L) setting...
February 9, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38431522/treatment-pattern-healthcare-resource-utilization-and-symptom-burden-among-patients-with-triple-class-exposed-multiple-myeloma-a-population-based-cohort-study
#29
JOURNAL ARTICLE
Hira Mian, Hsien Seow, Gregory R Pond, Anastasia Gayowsky, Ronan Foley, Amaris Balistky, Mohammed Ebraheem, Christopher Cipkar, Hyra Sapru, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alissa Visram
PURPOSE: This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refractory patents with multiple myeloma (MM) receiving a subsequent line of treatment (LOT). METHODS: This is a retrospective observational cohort study using administrative databases in Ontario, Canada. Outcomes were captured for TCE patients receiving a subsequent LOT and included: treatment regimen details, time to next treatment (TTNT), overall survival (OS), health care utilization, palliative care referral, and patient reported symptoms...
February 14, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38431521/outcome-of-patients-with-relapsed-acute-promyelocytic-leukemia
#30
JOURNAL ARTICLE
Koji Sasaki, Farhad Ravandi, Tapan Kadia, Courtney D DiNardo, Musa Yilmaz, Nicholas Short, Elias Jabbour, Keyur P Patel, Sanam Loghavi, Sherry Pierce, Gautam Borthakur, Hagop Kantarjian
BACKGROUND: The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal therapy for APL relapse is believed to require autologous or allogeneic stem cell transplantation (SCT) based on historical experience. STUDY AIMS: To evaluate the outcome of patients with relapsed APL before and after the era of ATRA-ATO. PATIENTS AND METHODS: We reviewed 61 patients with relapsed APL treated from November 1991 to June 2023; 31 patients (51%) received modern therapy with the combination of ATRA and ATO with and without idarubicin and gemtuzumab ozogamicin (GO)...
February 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38430810/cellular-therapies-in-older-adults-with-hematological-malignancies-a-case-based-state-of-the-art-review
#31
JOURNAL ARTICLE
Nina Rosa Neuendorff, Abdullah Khan, Fabian Ullrich, Samuel Yates, Srinivas Devarakonda, Richard J Lin, Bastian von Tresckow, Raul Cordoba, Andrew Artz, Ashley E Rosko
Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor- (CAR-) T cell therapies are essential treatment modalities for many hematological malignancies. Although their use in older adults has substantially increased within the past decades, cellular therapies represent intensive treatment approaches that exclude a large percentage of older adults due to comorbidities and frailty. Under- and overtreatment in older adults with hematologic malignancy is a challenge and many treatment decisions are influenced by chronologic age...
February 29, 2024: Journal of Geriatric Oncology
https://read.qxmd.com/read/38429222/hypomethylating-agents-and-venetoclax-for-acute-myeloid-leukemia-relapsed-after-hematopoietic-stem-cell-transplant
#32
JOURNAL ARTICLE
Filip Ionescu, Jerel C David, Apoorva Ravichandran, David A Sallman, Kendra Sweet, Rami S Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E Lancet
BACKGROUND: Hypomethylating agent + venetoclax is an effective frontline combination for acute myeloid leukemia, but its efficacy and safety in post-allogeneic hematopoietic cell transplant (alloHCT) relapse remain underexplored. Outcomes have been poor for this population, with no standard treatment. PATIENTS AND METHODS: We retrospectively analyzed 72 Ven-naïve patients who received hypomethylating agents + venetoclax at relapse following alloHCT and aimed to evaluate the rates of complete remission with or without hematologic recovery (CR/CRi) and minimal residual disease (MRD) negativity, CR/CRi duration, and overall survival...
February 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38429221/efficacy-and-safety-of-children-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-after-anti-cd19-car-t-cell-therapy-without-bridging-transplantation
#33
JOURNAL ARTICLE
Qianwen Shang, Lian Xue, Aidong Lu, Yueping Jia, YingXi Zuo, Huimin Zeng, Leping Zhang
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have demonstrated significant efficacy in achieving complete remission (CR) in pediatric patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, a considerable number of patients experience relapse within 1 year after CAR T-cell therapy, leading to an extremely poor prognosis, particularly in patients without bridging transplantation. MATERIALS AND METHODS: In our study, we investigated 42 children with R/R B-ALL who underwent anti-CD19 CAR T-cell therapy without bridging transplantation at our center...
February 7, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38415259/the-impact-of-gut-microbial-signals-on-hematopoietic-stem-cells-and-the-bone-marrow-microenvironment
#34
REVIEW
Xiru Liu, Hao Zhang, Guolin Shi, Xinmin Zheng, Jing Chang, Quande Lin, Zhenhao Tian, Hui Yang
Hematopoietic stem cells (HSCs) undergo self-renewal and differentiation in the bone marrow, which is tightly regulated by cues from the microenvironment. The gut microbiota, a dynamic community residing on the mucosal surface of vertebrates, plays a crucial role in maintaining host health. Recent evidence suggests that the gut microbiota influences HSCs differentiation by modulating the bone marrow microenvironment through microbial products. This paper comprehensively analyzes the impact of the gut microbiota on hematopoiesis and its effect on HSCs fate and differentiation by modifying the bone marrow microenvironment, including mechanical properties, inflammatory signals, bone marrow stromal cells, and metabolites...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38403505/azacitidine-post-transplant-maintenance-improves-disease-progression-in-high-risk-acute-myeloid-leukemia-and-myelodysplastic-syndrome
#35
JOURNAL ARTICLE
Oren Pasvolsky, Rima M Saliba, Uday R Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Partow Kebriaei, Richard Champlin, Naval Daver, Courtney Dinardo, Nicholas J Short, Elizabeth J Shpall, Betül Oran
BACKGROUND: Maintenance after allogeneic hematopoietic cell transplantation (alloHCT) with hypomethylating agents has yielded conflicting results. MATERIALS AND METHODS: We conducted a single center retrospective matched-control analysis with the study group (5-azacitidine [AZA] group) including adults with FLT3-negative acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received post-transplant AZA maintenance off clinical trial (n = 93). A matched control group was comprised of contemporaneous AML/MDS patients who did not receive any maintenance (n = 357)...
February 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38398467/exploring-the-therapeutic-potential-of-ganoderma-lucidum-in-cancer
#36
REVIEW
Gabriella Cancemi, Santino Caserta, Sebastiano Gangemi, Giovanni Pioggia, Alessandro Allegra
Triterpenoids, such as ganoderic acid, and polysaccharides, including β-D-glucans, α-D-glucans, and α-D-mannans, are the main secondary metabolites of the medicinal fungus Ganoderma lucidum . There is evidence of the effects of ganoderic acid in hematological malignancies, whose mechanisms involve the stimulation of immune response, the macrophage-like differentiation, the activation of MAP-K pathway, an IL3-dependent cytotoxic action, the induction of cytoprotective autophagy, and the induction of apoptosis...
February 18, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38390807/plentiplex%C3%A2-myd88-waldenstr%C3%A3-m-lymphoma-qpcr-assay-a-highly-sensitive-method-for-detection-of-myd88-l265p-mutation
#37
JOURNAL ARTICLE
Marcello Viscovo, Mia de Laurent Clemmensen, Federica Fosso, Elena Maiolo, Francesco Autore, Luca Laurenti, Stefan Hohaus, Patrizia Chiusolo
INTRODUCTION: Agarose gel-based conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays are currently used for sensitive detection and quantification of MYD88 L265P mutation. Visual inspection of an agarose gel can often be ambiguous. We propose a new allele-specific quantification PCR (AS-qPCR) assay, PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay, that uses Intercalating Nucleic Acid (INA®) technology for increased affinity and specificity...
February 23, 2024: International Journal of Laboratory Hematology
https://read.qxmd.com/read/38384127/parameters-of-body-composition-do-not-predict-survival-in-patients-with-multiple-myeloma-undergoing-autologous-stem-cell-transplantation
#38
JOURNAL ARTICLE
Felix Barajas Ordonez, Denise Wolleschak, Yannic Zeller, Mattes Hinnerichs, Pablo Rodríguez-Feria, Anar Aghayev, Martin Mikusko, Jan Borggrefe, Dimitrios Mougiakakos, Alexey Surov
Studies regarding the influence of body composition parameters as predictors on overall survival (OS) in patients with multiple myeloma (MM) are scarce. OS and progression-free survival (PFS) were retrospectively assessed in 129 patients with MM undergoing autologous stem cell transplantation (ASCT) after a follow-up of 2 years. A computed tomography (CT) based semi-automated assessment of body composition was performed. No statistically significant differences were noted in 2-year OS, PFS, or post-transplant adverse events in the body composition groups of subcutaneous adipose tissue (SAT) (low vs...
February 21, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38378362/venetoclax-and-cobimetinib-in-relapsed-refractory-aml-a-phase-1b-trial
#39
JOURNAL ARTICLE
Marina Y Konopleva, Monique Dail, Naval G Daver, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Agostino Tafuri, Joseph M Brandwein, Arnaud Pigneux, Bayard L Powell, Pierre Fenaux, Rebecca L Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Diana Dunshee, Habib Hamidi, Marion G Ott, Wan-Jen Hong, Michael Andreeff
BACKGROUND: Therapies for relapsed/refractory acute myeloid leukemia remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. PATIENTS AND METHODS: This phase 1b trial evaluated venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor, plus cobimetinib, a MEK1/2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia, ineligible for cytotoxic chemotherapy. Two-dimensional dose-escalation was performed for venetoclax dosed daily, and for cobimetinib dosed on days 1-21 of each 28-day cycle...
January 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38369437/optimizing-the-car-t-cell-therapy-experience-in-multiple-myeloma-clinical-pearls-from-an-expert-roundtable
#40
JOURNAL ARTICLE
Sikander Ailawadhi, Leyla Shune, Sandy W Wong, Yi Lin, Krina Patel, Sundar Jagannath
Chimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers (HCPs), including considerations for each step in the CAR-T therapy process. Referring HCPs should initiate conversations with HCPs at CAR-T capable centers earlier in the treatment journey, even before patients are eligible for CAR-T therapy, particularly for patients from underserved populations and patients with high-risk disease, to ensure adequate time for logistical planning and patient education...
February 1, 2024: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
56171
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.